Recombinant KOD polymerase
By modifying specific amino acid residues of KOD polymerase to form a KOD polymerase mutant, the problems of short sequencing read length and slow reaction rate in SBS sequencing are solved, achieving a faster catalytic reaction rate and a longer sequencing read length.
Patent Information
- Application Number
- CN201980051755.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-09-03
- Filing Date
- 2019-08-26
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2039-08-26
AI Technical Summary
Existing SBS sequencing technology suffers from short read lengths and slow reaction rates.
By modifying specific amino acid residues of KOD polymerase, especially by mutating amino acid residues at positions 408 and 409, and combining this with modifications at other positions in the amino acid sequence, KOD polymerase mutants are formed, thereby enhancing its DNA polymerization activity.
It improved the catalytic reaction rate of DNA polymerase and the sequencing read length, thus shortening the sequencing reaction time.
Smart Images

Figure GPA0000300227910000101 
Figure GPA0000300227910000111 
Figure GPA0000300227910000121
Abstract
Description
Technical Field
[0001] The invention relates to the field of biotechnology, in particular to a recombinant KOD polymerase. Background Art
[0002] The role of DNA polymerase is to quickly and accurately replicate DNA, which can accurately transmit genetic information and maintain the stability of genetic material for living organisms. There are five kinds of DNA polymerases in Escherichia coli, which are divided into several types such as A, B, and C according to the difference in sequence homology of DNA polymerase. The overall folding structure of DNA polymerase is similar to human hands, which is divided into three parts: palm, thumb and finger. Although the structure of the domain of the fingers and palm of different types of DNA polymerases will change greatly, the palm area difference of catalysis is smaller. The main amino acid sequence of the active site of DNA polymerase is conservative, but these conservative enzyme active sites are also relatively easy to change, and the activity of DNA polymerase can be kept not significantly decreased by adding non-natural specific dNTP (see patent No. 6602695 of Patel etc.).
[0003] KOD DNA polymerase belongs to the B-family DNA polymerase, which can replicate DNA quickly and accurately. It is a heat-resistant DNA polymerase with a wide range of applications. One of the most important applications is in genome sequencing, such as SBS sequencing. The SBS sequencing method uses nucleotides with modified 3' sugar hydroxyl groups to block the addition of other nucleotides. The use of nucleotides with 3' blocking groups allows nucleotides to be incorporated into polynucleotide chains in a controlled manner. After each nucleotide is added, the presence of the 3' blocking group prevents other nucleotides from being added to the chain. After removing the blocking group, the natural free 3' hydroxyl group is restored for the addition of the next nucleotide. However, there are many technical problems with SBS sequencing, such as short sequencing read lengths and slow reaction rates.
[0004] Invention Disclosure
[0005] In order to obtain a DNA polymerase with a fast catalytic reaction rate or a nucleotide with a 3' blocking group added to SBS sequencing, the present invention provides the following technical solution:
[0006] One object of the present invention is to provide a KOD polymerase mutant.
[0007] The KOD polymerase mutant provided by the present invention is a protein, which is the protein shown in A below or its derivative:
[0008] The protein shown in A) is a protein having DNA polymerase activity obtained by modifying the amino acid residues at positions 408 and 409 in the amino acid sequence of wild-type KOD DNA polymerase;
[0009] The derivative of the protein shown in A) is a protein derived from A) with a tag sequence added to the end of the amino acid sequence of the protein shown in A) and having DNA polymerase activity.
[0010] Alternatively, the present invention also provides a KOD polymerase mutant, which is a protein, which is a protein or a derivative thereof as shown in B below:
[0011] B) The protein shown is a protein having DNA polymerase activity obtained by modifying the amino acid residues at positions 408 and 409 in the amino acid sequence of the wild-type KOD type DNA polymerase, and modifying at least one of the amino acid residues at positions 500, 664, 351, 675, 385, 710, 674, 735, 736, 606, 709, 347, 349, 590, 676, 389, 589, 680, 384, 496 and 383 of the amino acid sequence of the wild-type KOD type DNA polymerase;
[0012] The derivative of the protein shown in B) is a protein derived from B) with a tag sequence added to the end of the amino acid sequence of the protein shown in B) and having DNA polymerase activity.
[0013] The protein shown in B) above is a KOD-type DNA polymerase mutant, specifically a single point mutant in Table 1 of the Examples.
[0014] Alternatively, the present invention also provides a KOD polymerase mutant, which is a protein, which is a protein or a derivative thereof as shown in C below:
[0015] C) The protein shown is a protein having DNA polymerase activity obtained by modifying the amino acid residues at positions 408 and 409 in the amino acid sequence of the wild-type KOD type DNA polymerase, and modifying at least two of the amino acid residues at positions 500, 664, 351, 675, 385, 710, 674, 735, 736, 606, 709, 347, 349, 590, 676, 389, 589, 680, 384, 496, 383 and 485 of the amino acid sequence of the wild-type KOD type DNA polymerase;
[0016] The derivative of the protein shown in C) is a protein derived from C) with a tag sequence added to the end of the amino acid sequence of the protein shown in C) and having DNA polymerase activity.
[0017] Among the above proteins, the protein shown in C) is a protein having DNA polymerase activity obtained by modifying the amino acid residues at positions 408 and 409 in the amino acid sequence of the wild-type KOD type DNA polymerase, and modifying at least 3 amino acid residues among 22 positions 500, 664, 351, 675, 385, 710, 674, 735, 736, 606, 709, 347, 349, 590, 676, 389, 589, 680, 384, 496, 383 and 485 of the amino acid sequence of the wild-type KOD type DNA polymerase.
[0018] Among the above proteins, the protein shown in C) is a protein having DNA polymerase activity obtained by modifying the amino acid residues at positions 408 and 409 in the amino acid sequence of the wild-type KOD type DNA polymerase, and modifying at least 4 amino acid residues among 22 positions 500, 664, 351, 675, 385, 710, 674, 735, 736, 606, 709, 347, 349, 590, 676, 389, 589, 680, 384, 496, 383 and 485 of the amino acid sequence of the wild-type KOD type DNA polymerase.
[0019] Among the above proteins, the protein shown in C) is a protein having DNA polymerase activity obtained by modifying the amino acid residues at positions 408 and 409 in the amino acid sequence of the wild-type KOD type DNA polymerase, and modifying at least 5 amino acid residues among 22 positions 500, 664, 351, 675, 385, 710, 674, 735, 736, 606, 709, 347, 349, 590, 676, 389, 589, 680, 384, 496, 383 and 485 of the amino acid sequence of the wild-type KOD type DNA polymerase.
[0020] Among the above proteins, the protein shown in C) is a protein having DNA polymerase activity obtained by modifying the amino acid residues at positions 408 and 409 in the amino acid sequence of the wild-type KOD type DNA polymerase, and modifying at least 6 amino acid residues among 22 positions 500, 664, 351, 675, 385, 710, 674, 735, 736, 606, 709, 347, 349, 590, 676, 389, 589, 680, 384, 496, 383 and 485 of the amino acid sequence of the wild-type KOD type DNA polymerase.
[0021] Among the above proteins, the protein shown in C) is a protein having DNA polymerase activity obtained by modifying the amino acid residues at positions 408 and 409 in the amino acid sequence of the wild-type KOD type DNA polymerase, and modifying at least 7 amino acid residues among 22 positions 500, 664, 351, 675, 385, 710, 674, 735, 736, 606, 709, 347, 349, 590, 676, 389, 589, 680, 384, 496, 383 and 485 of the amino acid sequence of the wild-type KOD type DNA polymerase.
[0022] Among the above proteins, the protein shown in C) is a protein having DNA polymerase activity obtained by modifying the amino acid residues at positions 408 and 409 in the amino acid sequence of the wild-type KOD-type DNA polymerase, and modifying the amino acid residues at positions 389, 589, 676, 680, 383, 384 and 485 of the amino acid sequence of the wild-type KOD-type DNA polymerase;
[0023] Or, the protein shown in C) is obtained by modifying the amino acid residues at positions 408 and 409 in the amino acid sequence of the wild-type KOD-type DNA polymerase, and modifying the amino acid sequence of the wild-type KOD-type DNA polymerase by mutating the alanine residues at positions 589, 676, 680, 383, 384, 709, and 485 to glutamic acid residues, to obtain a protein having DNA polymerase activity;
[0024] Or, the protein shown in C) is a protein having DNA polymerase activity obtained by modifying the amino acid residues at positions 408 and 409 in the amino acid sequence of the wild-type KOD type DNA polymerase, and modifying the amino acid residues at positions 589, 676, 680, 383, 384 and 485 of the amino acid sequence of the wild-type KOD type DNA polymerase.
[0025] Or, the protein shown in C) is a protein having DNA polymerase activity obtained by modifying the amino acid residues at positions 408 and 409 in the amino acid sequence of a wild-type KOD-type DNA polymerase, and modifying the amino acid residues at positions 349, 589, 676, 680, 496 and 485 of the amino acid sequence of the wild-type KOD-type DNA polymerase;
[0026] Or, the protein shown in C) is a protein having DNA polymerase activity obtained by modifying the amino acid residues at positions 408 and 409 in the amino acid sequence of a wild-type KOD-type DNA polymerase, and modifying the amino acid residues at positions 674, 589, 680, 383, 384 and 485 of the amino acid sequence of the wild-type KOD-type DNA polymerase;
[0027] Or, the protein shown in C) is a protein having DNA polymerase activity obtained by modifying the amino acid residues at positions 408 and 409 in the amino acid sequence of the wild-type KOD-type DNA polymerase, and modifying the amino acid residues at positions 589, 680, 676, 383, and 384 in the amino acid sequence of the wild-type KOD-type DNA polymerase;
[0028] Or, the protein shown in C) is a protein having DNA polymerase activity obtained by modifying the amino acid residues at positions 408 and 409 in the amino acid sequence of the wild-type KOD-type DNA polymerase, and modifying the amino acid residues at positions 389, 674, 589, 680, and 485 of the amino acid sequence of the wild-type KOD-type DNA polymerase;
[0029] Or, the protein shown in C) is obtained by modifying the amino acid residues at positions 408 and 409 in the amino acid sequence of the wild-type KOD-type DNA polymerase, and modifying the amino acid residues at positions 676, 589, 680, 384, and 485 of the amino acid sequence of the wild-type KOD-type DNA polymerase to obtain a protein with DNA polymerase activity;
[0030] Or, the protein shown in C) is obtained by modifying the amino acid residues at positions 408 and 409 in the amino acid sequence of the wild-type KOD-type DNA polymerase, and modifying the amino acid residues at positions 589, 680, and 709 in the amino acid sequence of the wild-type KOD-type DNA polymerase to obtain a protein with DNA polymerase activity;
[0031] Or, the protein shown in C) is a protein having DNA polymerase activity obtained by modifying the amino acid residues at positions 408 and 409 in the amino acid sequence of the wild-type KOD type DNA polymerase, and modifying the amino acid residues at positions 674, 589, 680, and 485 of the amino acid sequence of the wild-type KOD type DNA polymerase.
[0032] Or, the protein shown in C) is obtained by modifying the amino acid residues at positions 408 and 409 in the amino acid sequence of the wild-type KOD-type DNA polymerase, and modifying the amino acid residues at positions 676, 589, 680, and 485 of the amino acid sequence of the wild-type KOD-type DNA polymerase to obtain a protein with DNA polymerase activity;
[0033] Or, the protein shown in C) is obtained by modifying the amino acid residues at positions 408 and 409 in the amino acid sequence of the wild-type KOD-type DNA polymerase, and modifying the amino acid residues at positions 709, 589, and 485 of the amino acid sequence of the wild-type KOD-type DNA polymerase to obtain a protein with DNA polymerase activity;
[0034] Or, the protein shown in C) is a protein having DNA polymerase activity obtained by modifying the amino acid residues at positions 408 and 409 in the amino acid sequence of the wild-type KOD type DNA polymerase, and modifying the amino acid residues at positions 709 and 589 in the amino acid sequence of the wild-type KOD type DNA polymerase.
[0035] The protein shown in C) above is a KOD-type DNA polymerase mutant, specifically a multi-point mutant in Table 2 of the Examples.
[0036] In the above protein, the modification is amino acid substitution.
[0037] In the above protein, the manner of substitution of each amino acid is as follows:
[0038] Alanine at position 675 is substituted with phenylalanine or methionine;
[0039] Glutamic acid at position 385 is substituted with methionine or tryptophan;
[0040] Isoleucine at position 710 is substituted with serine or histidine;
[0041] Lysine at position 674 is substituted with leucine or cysteine;
[0042] Asparagine at position 735 was substituted with histidine;
[0043] The glutamine at position 736 was replaced with glutamic acid or alanine;
[0044] The arginine at position 606 is substituted with histidine or methionine;
[0045] The arginine at position 709 is substituted with serine or histidine;
[0046] The serine at position 347 was substituted with isoleucine or methionine;
[0047] The threonine at position 349 is substituted with phenylalanine or isoleucine;
[0048] The threonine at position 590 is substituted with lysine or leucine;
[0049] The threonine at position 676 is substituted with lysine or tyrosine;
[0050] The valine at position 389 was replaced by isoleucine or methionine;
[0051] The valine at position 589 was replaced with histidine or glutamine;
[0052] The valine at position 680 was replaced by methionine or glutamic acid;
[0053] The tyrosine at position 384 is replaced by phenylalanine or tryptophan;
[0054] The tyrosine at position 496 is replaced by leucine or isoleucine;
[0055] The serine at position 383 was substituted with threonine;
[0056] Alanine at position 485 was mutated to glutamic acid;
[0057] The leucine (L) at position 408 was mutated to isoleucine (I);
[0058] The tyrosine (Y) at position 409 was mutated to alanine (A);
[0059] Alanine at position 500 was mutated to aspartic acid or glycine;
[0060] Glutamic acid at position 664 was mutated to leucine or methionine;
[0061] Asparagine at position 351 was mutated to tyrosine or histidine.
[0062] In the above protein, the amino acid sequence of the wild-type KOD DNA polymerase is Sequence 1. The DNA molecule encoding the above protein is also within the scope of protection of the present invention.
[0063] The expression cassette, recombinant vector, recombinant bacteria or transgenic cell line containing the above DNA molecule also fall within the scope of protection of the present invention.
[0064] The application of the above protein in at least one of the following 1)-5) is also within the scope of protection of the present invention:
[0065] 1) As a DNA polymerase;
[0066] 2) catalyze DNA replication and / or catalyze DNA amplification;
[0067] 3) Perform nucleic acid sequencing;
[0068] 4) preparing products for catalyzing DNA replication and / or catalyzing DNA amplification;
[0069] 5) Preparing products for nucleic acid sequencing.
[0070] The use of the above DNA molecule or the above expression cassette, recombinant vector, recombinant bacteria or transgenic cell line in at least one of the following 1)-6) is also within the scope of protection of the present invention:
[0071] 1) preparing DNA polymerase;
[0072] 2) catalyze DNA replication and / or catalyze DNA amplification;
[0073] 3) Perform nucleic acid sequencing;
[0074] 4) Preparation of DNA polymerase products;
[0075] 5) preparing products for catalyzing DNA replication and / or catalyzing DNA amplification;
[0076] 6) Preparing products for nucleic acid sequencing.
[0077] In the above application, the sequencing is SBS sequencing;
[0078] The nucleic acid is DNA or RNA or a whole genome.
[0079] In the above application, the product is a test kit. SEQUENCE LISTING <110> Shenzhen BGI Life Sciences Institute <120> Recombinant KOD polymerase <160> 6 <170> PatentIn version 3.5 <210> 1 <211> 774 <212> PRT <213> Artificial sequence <400> 1 Met Ile Leu Asp Thr Asp Tyr Ile Thr Glu Asp Gly Lys Pro Val Ile 1 5 10 15 Arg Ile Phe Lys Lys Glu Asn Gly Glu Phe Lys Ile Glu Tyr Asp Arg 20 25 30 Thr Phe Glu Pro Tyr Phe Tyr Ala Leu Leu Lys Asp Asp Ser Ala Ile 35 40 45 Glu Glu Val Lys Lys Ile Thr Ala Glu Arg His Gly Thr Val Val Thr 50 55 60 Val Lys Arg Val Glu Lys Val Gln Lys Lys Phe Leu Gly Arg Pro Val 65 70 75 80 Glu Val Trp Lys Leu Tyr Phe Thr His Pro Gln Asp Val Pro Ala Ile 85 90 95 Arg Asp Lys Ile Arg Glu His Pro Ala Val Ile Asp Ile Tyr Glu Tyr 100 105 110 Asp Ile Pro Phe Ala Lys Arg Tyr Leu Ile Asp Lys Gly Leu Val Pro 115 120 125 Met Glu Gly Asp Glu Glu Leu Lys Met Leu Ala Phe Ala Ile Ala Thr 130 135 140 Leu Tyr His Glu Gly Glu Glu Phe Ala Glu Gly Pro Ile Leu Met Ile 145 150 155 160 Ser Tyr Ala Asp Glu Glu Gly Ala Arg Val Ile Thr Trp Lys Asn Val 165 170 175 Asp Leu Pro Tyr Val Asp Val Val Ser Thr Glu Arg Glu Met Ile Lys 180 185 190 Arg Phe Leu Arg Val Val Lys Glu Lys Asp Pro Asp Val Leu Ile Thr 195 200 205 Tyr Asn Gly Asp Asn Phe Asp Phe Ala Tyr Leu Lys Lys Arg Cys Glu 210 215 220 Lys Leu Gly Ile Asn Phe Ala Leu Gly Arg Asp Gly Ser Glu Pro Lys 225 230 235 240 Ile Gln Arg Met Gly Asp Arg Phe Ala Val Glu Val Lys Gly Arg Ile 245 250 255 His Phe Asp Leu Tyr Pro Val Ile Arg Arg Thr Ile Asn Leu Pro Thr 260 265 270 Tyr Thr Leu Glu Ala Val Tyr Glu Ala Val Phe Gly Gln Pro Lys Glu 275 280 285 Lys Val Tyr Ala Glu Glu Ile Thr Thr Ala Trp Glu Thr Gly Glu Asn 290 295 300 Leu Glu Arg Val Ala Arg Tyr Ser Met Glu Asp Ala Lys Val Thr Tyr 305 310 315 320 Glu Leu Gly Lys Glu Phe Leu Pro Met Glu Ala Gln Leu Ser Arg Leu 325 330 335 Ile Gly Gln Ser Leu Trp Asp Val Ser Arg Ser Ser Thr Gly Asn Leu 340 345 350 Val Glu Trp Phe Leu Leu Arg Lys Ala Tyr Glu Arg Asn Glu Leu Ala 355 360 365 Pro Asn Lys Pro Asp Glu Lys Glu Leu Ala Arg Arg Arg Gln Ser Tyr 370 375 380 Glu Gly Gly Tyr Val Lys Glu Pro Glu Arg Gly Leu Trp Glu Asn Ile 385 390 395 400 Val Tyr Leu Asp Phe Arg Ser Leu Tyr Pro Ser Ile Ile Ile Thr His 405 410 415 Asn Val Ser Pro Asp Thr Leu Asn Arg Glu Gly Cys Lys Glu Tyr Asp 420 425 430 Val Ala Pro Gln Val Gly His Arg Phe Cys Lys Asp Phe Pro Gly Phe 435 440 445 Ile Pro Ser Leu Leu Gly Asp Leu Leu Ala Glu Arg Gln Lys Ile Lys 450 455 460 Lys Lys Met Lys Ala Thr Ile Asp Pro Ile Glu Arg Lys Leu Leu Asp 465 470 475 480 Tyr Arg Gln Arg Glu Ile Lys Ile Leu Ala Asn Ser Tyr Tyr Gly Tyr 485 490 495 Tyr Gly Tyr Ala Arg Ala Arg Trp Tyr Cys Lys Glu Cys Ala Glu Ser 500 505 510 Val Thr Ala Trp Gly Arg Glu Tyr Ile Thr Met Thr Ile Lys Glu Ile 515 520 525 Glu Glu Lys Tyr Gly Phe Lys Val Ile Tyr Ser Asp Thr Asp Gly Phe 530 535 540 Phe Ala Thr Ile Pro Gly Ala Asp Ala Glu Thr Val Lys Lys Lys Ala 545 550 555 560 Met Glu Phe Leu Lys Tyr Ile Asn Ala Lys Leu Pro Gly Ala Leu Glu 565 570 575 Leu Glu Tyr Glu Gly Phe Tyr Lys Arg Gly Phe Phe Val Thr Lys Lys 580 585 590 Lys Tyr Ala Val Ile Asp Glu Glu Gly Lys Ile Thr Thr Arg Gly Leu 595 600 605 Glu Ile Val Arg Arg Asp Trp Ser Glu Ile Ala Lys Glu Thr Gln Ala 610 615 620 Arg Val Leu Glu Ala Leu Leu Lys Asp Gly Asp Val Glu Lys Ala Val 625 630 635 640 Arg Ile Val Lys Glu Val Thr Glu Lys Leu Ser Lys Tyr Glu Val Pro 645 650 655 Pro Glu Lys Leu Val Ile His Glu Gln Ile Thr Arg Asp Leu Lys Asp 660 665 670 Tyr Lys Ala Thr Gly Pro His Val Ala Val Ala Lys Arg Leu Ala Ala 675 680 685 Arg Gly Val Lys Ile Arg Pro Gly Thr Val Ile Ser Tyr Ile Val Leu 690 695 700 Lys Gly Ser Gly Arg Ile Gly Asp Arg Ala Ile Pro Phe Asp Glu Phe 705 710 715 720 Asp Pro Thr Lys His Lys Tyr Asp Ala Glu Tyr Tyr Ile Glu Asn Gln 725 730 735 Val Leu Pro Ala Val Glu Arg Ile Leu Arg Ala Phe Gly Tyr Arg Lys 740 745 750 Glu Asp Leu Arg Tyr Gln Lys Thr Arg Gln Val Gly Leu Ser Ala Trp 755 760 765 Leu Lys Pro Lys Gly Thr 770 <210> 2 <211> 2325 <212> DNA <213> Artificial sequence <400> 2 atgattctgg acaccgatta catcaccgaa gatggcaagc cagttatccg cattttcaaa 60 aaagagaatg gtgaattcaa gatcgaatat gatcgtacct tcgagccgta cttctatgct 120 ctgctgaaag acgatagcgc gattgaggag gtcaagaaaa tcaccgcgga gcgtcacggt 180 acggttgtta ccgtgaaacg cgtggagaaa gtccagaaga aatttctggg tcgcccggtt 240 gaagtgtgga agctgtactt tacgcatccg caagatgttc cggcgattcg cgataagatt 300 cgtgagcacc cggcagtcat tgacatctac gagtatgaca ttccgttcgc caagcgttat 360 ctgatcgata agggtctggt cccgatggag ggtgacgaag aactgaagat gctggcgttc 420 gccatcgcca ctctgtacca cgagggtgaa gagtttgccg agggtccgat cttgatgatt 480 tcctacgcgg acgaagaggg cgcacgtgtt atcacgtgga aaaatgttga tctgccgtat 540 gttgacgtcg taagcaccga gcgtgagatg atcaaacgtt ttctgcgcgt tgttaaagaa 600 aaagatcctg acgtgctgat cacctacaac ggtgacaatt tcgatttcgc gtacctgaag 660 aaacgttgcg aaaaactggg tattaacttc gcgctgggtc gcgatggctc tgaaccgaag 720 atccagcgca tgggtgatcg ttttgcggtc gaggtgaagg gtcgcattca tttcgacctg 780 tacccggtga ttcgtcgtac catcaacttg ccgacttaca ccctggaagc cgtctatgaa 840 gctgtatttg gtcaaccgaa agaaaaagtg tacgctgagg aaattacgac ggcgtgggaa 900 accggtgaga acctggagcg cgttgcacgt tattctatgg aggacgcgaa agttacctac 960 gaactgggta aagagttcct gccgatggag gcccaactgt cccgtctgat cggccaaagc 1020 ctgtgggacg ttagccgcag cagcaccggt aacttagttg aatggttctt gctgcgtaag 1080 gcatacgaac gcaatgagct ggcgccgaac aaaccggacg agaaagaatt ggcgcgtcgc 1140 cgccagagct atgagggtgg ttatgtcaaa gaaccggagc gcggcttgtg ggagaacatc 1200 gtctatttgg atttcgtag cctgtatccg agcatcatta tcacgcataa tgtgagcccg 1260 gatacgttga atcgtgaggg ctgtaaggaa tacgacgtgg cgcctcaggt tggccaccgt 1320 ttctgcaagg actttccggg ctttatcccg agcctgctgg gtgatttgct ggaggaacgt 1380 cagaaaatca agaagaagat gaaagcaacc attgatccga tcgagcgcaa attactggac 1440 taccgtcaac gtgcaatcaa gatcctggcg aattcgtatt atggttacta tggctacgcg 1500 cgtgcgcgct ggtattgcaa agagtgtgcc gagagcgtga ccgcttgggg tcgtgagtac 1560 attaccatga cgatcaaaga gattgaagag aatacggct ttaaggttat ctatagcgac 1620 accgacggtt tctttgcaac tatccctggc gcagacgcag aaaccgttaa gaaaaaggca 1680 atggagtttc tgaagtatat caacgcgaag ttgccaggcg ccctggaact ggagtacgag 1740 ggcttctaca agcgtggctt tttcgtgacg aaaaagaaat acgctgttat tgatgaagag 1800 ggcaagatca cgacccgtgg cctggaaatt gtgcgccgtg attggagcga aattgcaaaa 1860 gaaacgcaag cgcgtgtgct ggaagcgctg ctgaaggacg gcgacgtcga aaaagctgtg 1920 cgtattgtta aagaggtcac cgagaagctg agcaaatacg aggtcccgcc agagaaattg 1980 gtgattcacg aacagattac gcgtgacctg aaagactata aggccaccgg tccgcatgtc 2040 gcagtggcga agcgcctggc ggctcgcggt gtgaagatcc gtccgggtac cgtcattagc 2100 tatatcgtgc tgaagggcag cggtcgtatc ggcgaccgtg cgattccgtt cgacgaattt 2160 gatccgacca aacacaaata tgatgcggaa tactatattg agaaccaagt gctgccagcc 2220 gttgagcgta ttctgcgcgc cttcggttac cgcaaggaag atctgcgtta ccagaaaact 2280 cgtcaggcg gtctgtccgc atggctgaaa ccgaagggca cctga 2325 <210> 3 <211> 774 <212> PRT <213> Artificial sequence <400> 3 Met Ile Leu Asp Thr Asp Tyr Ile Thr Glu Asp Gly Lys Pro Val Ile 1 5 10 15 Arg Ile Phe Lys Lys Glu Asn Gly Glu Phe Lys Ile Glu Tyr Asp Arg 20 25 30 Thr Phe Glu Pro Tyr Phe Tyr Ala Leu Leu Lys Asp Asp Ser Ala Ile 35 40 45 Glu Glu Val Lys Lys Ile Thr Ala Glu Arg His Gly Thr Val Val Thr 50 55 60 Val Lys Arg Val Glu Lys Val Gln Lys Lys Phe Leu Gly Arg Pro Val 65 70 75 80 Glu Val Trp Lys Leu Tyr Phe Thr His Pro Gln Asp Val Pro Ala Ile 85 90 95 Arg Asp Lys Ile Arg Glu His Pro Ala Val Ile Asp Ile Tyr Glu Tyr 100 105 110 Asp Ile Pro Phe Ala Lys Arg Tyr Leu Ile Asp Lys Gly Leu Val Pro 115 120 125 Met Glu Gly Asp Glu Glu Leu Lys Met Leu Ala Phe Ala Ile Ala Thr 130 135 140 Leu Tyr His Glu Gly Glu Glu Phe Ala Glu Gly Pro Ile Leu Met Ile 145 150 155 160 Ser Tyr Ala Asp Glu Glu Gly Ala Arg Val Ile Thr Trp Lys Asn Val 165 170 175 Asp Leu Pro Tyr Val Asp Val Val Ser Thr Glu Arg Glu Met Ile Lys 180 185 190 Arg Phe Leu Arg Val Val Lys Glu Lys Asp Pro Asp Val Leu Ile Thr 195 200 205 Tyr Asn Gly Asp Asn Phe Asp Phe Ala Tyr Leu Lys Lys Arg Cys Glu 210 215 220 Lys Leu Gly Ile Asn Phe Ala Leu Gly Arg Asp Gly Ser Glu Pro Lys 225 230 235 240 Ile Gln Arg Met Gly Asp Arg Phe Ala Val Glu Val Lys Gly Arg Ile 245 250 255 His Phe Asp Leu Tyr Pro Val Ile Arg Arg Thr Ile Asn Leu Pro Thr 260 265 270 Tyr Thr Leu Glu Ala Val Tyr Glu Ala Val Phe Gly Gln Pro Lys Glu 275 280 285 Lys Val Tyr Ala Glu Glu Ile Thr Thr Ala Trp Glu Thr Gly Glu Asn 290 295 300 Leu Glu Arg Val Ala Arg Tyr Ser Met Glu Asp Ala Lys Val Thr Tyr 305 310 315 320 Glu Leu Gly Lys Glu Phe Leu Pro Met Glu Ala Gln Leu Ser Arg Leu 325 330 335 Ile Gly Gln Ser Leu Trp Asp Val Ser Arg Ser Ser Thr Gly Asn Leu 340 345 350 Val Glu Trp Phe Leu Leu Arg Lys Ala Tyr Glu Arg Asn Glu Leu Ala 355 360 365 Pro Asn Lys Pro Asp Glu Lys Glu Leu Ala Arg Arg Arg Gln Ser Tyr 370 375 380 Glu Gly Gly Tyr Val Lys Glu Pro Glu Arg Gly Leu Trp Glu Asn Ile 385 390 395 400 Val Tyr Leu Asp Phe Arg Ser Ile Ala Pro Ser Ile Ile Ile Thr His 405 410 415 Asn Val Ser Pro Asp Thr Leu Asn Arg Glu Gly Cys Lys Glu Tyr Asp 420 425 430 Val Ala Pro Gln Val Gly His Arg Phe Cys Lys Asp Phe Pro Gly Phe 435 440 445 Ile Pro Ser Leu Leu Gly Asp Leu Leu Ala Glu Arg Gln Lys Ile Lys 450 455 460 Lys Lys Met Lys Ala Thr Ile Asp Pro Ile Glu Arg Lys Leu Leu Asp 465 470 475 480 Tyr Arg Gln Arg Glue Ile Lys Ileu Only Ser Asn Tyr Tyr Gly Tyr 485,490,495 Tyr Gly Tyr Ala Arg Ala Arg Trp Tyr Cys Lys Glu Cys Ala Glu Ser 500 505 510 Val Thr Ala Trp Gly Arg Glu Tyr Ile Thr Met Thr Ile Lys Glu Ile 515,520,525 Glu Glu Lys Tyr Gly Phe Lys Val Ile Tyr Ser Asp Thr Asp Gly Phe 530 535 540 Phe Ala Thr Ile Pro Gly Ala Asp Ala Glu Thr Val Lys Lys Ala 545 550 555 560 Met Glu Phe Leu Lys Tyr Ile Asn Ala Lys Leu Pro Gly Ala Leu Glu 565,570,575 Leu Glu Tyr Glu Gly Phe Tyr Lys Arg Gly Phe Phe Val Thr Lys Lys 580,585,590 Lys Tyr Ala Val Ile Asp Glu Glu Gly Lys Ile Thr Thr Arg Gly Leu 595,600,605 Glu Ile Val Arg Arg Asp Trp Ser Glu Ile Ala Lys Glu Thr Gln Ala 610 615 620 Arg Val Leu Glu Ala Leu Leu Lys Asp Gly Asp Val Glu Lys Ala Val 625 630 635 640 Arg Ile Val Lys Glu Val Thr Glu Lys Leu Ser Lys Tyr Glu Val Pro 645 650 655 Pro Glu Lys Leu Val Ile His Glu Gln Ile Thr Arg Asp Leu Lys Asp 660 665 670 Tyr Lys Ala Thr Gly Pro His Val Ala Val Ala Lys Arg Leu Ala Ala 675 680 685 Arg Gly Val Lys Ile Arg Pro Gly Thr Val Ile Ser Tyr Ile Val Leu 690 695 700 Lys Gly Ser Gly Arg Ile Gly Asp Arg Ala Ile Pro Phe Asp Glu Phe 705 710 715 720 Asp Pro Thr Lys His Lys Tyr Asp Ala Glu Tyr Tyr Ile Glu Asn Gln 725 730 735 Val Leu Pro Ala Val Glu Arg Ile Leu Arg Ala Phe Gly Tyr Arg Lys 740 745 750 Glu Asp Leu Arg Tyr Gln Lys Thr Arg Gln Val Gly Leu Ser Ala Trp 755 760 765 Leu Lys Pro Lys Gly Thr 770 <210> 4 <211> 2325 <212> DNA <213> Artificial sequence <400> 4 atgattctgg acaccgatta catcaccgaa gatggcaagc cagttatccg cattttcaaa 60 aaagagaatg gtgaattcaa gatcgaatat gatcgtacct tcgagccgta cttctatgct 120 ctgctgaaag acgatagcgc gattgaggag gtcaagaaaa tcaccgcgga gcgtcacggt 180 acggttgtta ccgtgaaacg cgtggagaaa gtccagaaga aatttctggg tcgcccggtt 240 gaagtgtgga agctgtactt tacgcatccg caagatgttc cggcgattcg cgataagatt 300 cgtgagcacc cggcagtcat tgacatctac gagtatgaca ttccgttcgc caagcgttat 360 ctgatcgata agggtctggt cccgatggag ggtgacgaag aactgaagat gctggcgttc 420 gccatcgcca ctctgtacca cgagggtgaa gagtttgccg agggtccgat cttgatgatt 480 tcctacgcgg acgaagagg cgcacgtgtt atcacgtgga aaaatgttga tctgccgtat 540 gttgacgtcg taagcaccga gcgtgagatg atcaaacgtt ttctgcgcgt tgttaaagaa 600 aaagatcctg acgtgctgat cacctacaac ggtgacaatt tcgatttcgc gtacctgaag 660 aaacgttgcg aaaaactggg tattaacttc gcgctgggtc gcgatggctc tgaaccgaag 720 atccagcgca tgggtgatcg ttttgcggtc gaggtgaagg gtcgcattca tttcgacctg 780 tacccggtga ttcgtcgtac catcaacttg ccgacttaca ccctggaagc cgtctatgaa 840 gctgtatttg gtcaaccgaa agaaaaagtg tacgctgagg aaattacgac ggcgtgggaa 900 accggtgaga acctggagcg cgttgcacgt tattctatgg aggacgcgaa agttacctac 960 gaactgggta aagagttcct gccgatggag gcccaactgt cccgtctgat cggccaaagc 1020 ctgtgggacg ttagccgcag cagcaccggt aacttagttg aatggttctt gctgcgtaag 1080 gcatacgaac gcaatgagct ggcgccgaac aaaccggacg agaaagaatt ggcgcgtcgc 1140 cgccagagct atgagggtgg ttatgtcaaa gaaccggagc gcggcttgtg ggagaacatc 1200 gtctatttgg attttcgtag cattgcaccg agcatcatta tcacgcataa tgtgagcccg 1260 gatacgttga atcgtgaggg ctgtaaggaa tacgacgtgg cgcctcaggt tggccaccgt 1320 ttctgcaagg actttccggg ctttatcccg agcctgctgg gtgatttgct ggaggaacgt 1380 cagaaaatca agaagagat gaagcaacc attgatccga tcgagcgcaa attackggac 1440 taccgtcaac gtgcaatcaa gatcctggcg aattcgtatt atggttacta tggctacgcg 1500 cgtgcgcgct ggtattgca agagtgtgcc gagagcgtga ccgcttgggg tcgtgagtac 1560 attaccatga cgatcaaga gattgaagg aaatacggct tttaggttat ctatagcgac 1620 accgacggtt tctttgcac tatccctggc gcagacgcag aaccgttaa gaaaaaggca 1680 atggagtttc tgagtatat caacgcgaag ttgccaggcg ccctggact ggagtacgag 1740 ggcttctaca agcgtggctt ttcgtgacg aaaaagaaat acgcttt tgatgaagag 1800 ggcaagatca cgacccgtgg cctggaatt gtgcgccgtg attggagcga aattgcaaaa 1860 gaacgcaag cgcgtgtgct ggaagcgctg ctgaggacg gcgacgtcga aaagctgtg 1920 cgtattgtta aagaggtcac cgagaagctg agcaatacg aggtccccgcc agagaattg 1980 gtgattcacg aacagattac gcgtgacctg aaagactata aggccaccgg tccgcatgtc 2040 gcagtggcga agcgcctggc ggctcgcggt gtgaagagatcc gtccgggtac cgtcattagc 2100 tatatcgtgc tgaagggcag cggtcgtatc ggcgaccgtg cgattccgtt cgacgaattt 2160 gatccgacca aacacaaata tgatgcggaa tactatattg agaaccaagt gctgccagcc 2220 gttgagcgta ttctgcgcgc cttcggttac cgcaaggaag atctgcgtta ccagaaaact 2280 cgtcaggtcg gtctgtccgc atggctgaaa ccgaagggca cctga 2325 <210> 5 <211> 25 <212> DNA <213> Artificial sequence <400> 5 ggttttttta tggggggagt ttagg 25 <210> 6 <211> 25 <212> DNA <213> Artificial sequence <400> 6 catctcatct gtaacatcat tggca 25 BRIEF DESCRIPTION OF THE DRAWINGS
[0080] Figure 1 Schematic diagram of the structure of recombinant KOD DNA polymerase.
[0081] Figure 2 To detect the purity of wild-type KOD DNA polymerase fusion protein.
[0082] Best Mode for Carrying Out the Invention
[0083] Unless otherwise specified, the experimental methods used in the following examples are conventional methods.
[0084] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.
[0085] Example 1. Preparation of KOD DNA polymerase mutants
[0086] In the present invention, KOD DNA polymerase and its mutants are used in the Electra of DNA 2.0. TM The expression vector was constructed using the Cloning Reagents Kit, and the His tag was used for Ni column affinity purification.
[0087] 1. Preparation of wild-type KOD DNA polymerase
[0088] The amino acid sequence of the wild-type KOD DNA polymerase is Sequence 1 in the following sequence listing, and the encoding gene sequence is Sequence 2 in the following sequence listing.
[0089] 1. Construction of wild-type expression vector pD441-WT
[0090] The wild-type recombinant expression vector pD441-WT is a vector for expressing the wild-type KOD DNA polymerase encoding gene fused with his tag according to Electra T M Cloning Reagents Kit (DNA2.0, EKT-02) kit instructions and operating steps were used to recombinant into the vector pD441-pelB (DNA2.0, pD441-pelB). The resulting vector was fused with a His-tag encoding gene for wild-type KOD DNA polymerase, which was expressed through the signal peptide on the vector pD441-pelB.
[0091] The nucleotide sequence of the wild-type KOD DNA polymerase encoding gene fused with a His tag is a sequence obtained by connecting six His tag codons to the 3' end of sequence 2.
[0092] The amino acid sequence of the wild-type KOD DNA polymerase fusion protein is obtained by connecting 6 His tags to the C-terminus of the amino acids shown in sequence 1, as follows: Figure 1 , 1 is the signal peptide pelB; 2 is the fusion protein purification tag His; 3 is the wild-type KOD DNA polymerase.
[0093] 2. Construction of recombinant bacteria
[0094] The wild-type recombinant expression vector pD441-WT was introduced into E. coli BL21 competent cells (purchased from Quanshijin Biotechnology Co., Ltd.) and smeared on a plate containing 50 μg / ml of kanamycin to screen positive colonies. 3-5 positive colonies were selected and PCR identified using primers Cloning-F and Cloning-R. A fragment of 2800 bp in size was obtained, which was basically consistent with the expected theoretical value. The sequencing results were compared to determine the positive clone, which was named BL21 / pD441-WT.
[0095] Cloning-F: 5'GGTTTTTTTATGGGGGGAGTTTAGG 3' (sequence 5)
[0096] Cloning-R: 5'CATCTCATCTGTAACATCATTGGCA 3' (SEQ ID NO: 6)
[0097] 3. Expression and purification of wild-type KOD DNA polymerase fusion protein
[0098] Pick a single BL21 / pD441-WT colony and culture it in 50ml LB liquid medium (containing Kan 50μg / ml) at 37°C, 220rpm / min overnight. The next day, dilute it at 1:100 and transfer it to 1LL LB liquid medium (containing Kan 50μg / ml). Culture it in a shaking incubator at 37°C, 220rpm / min until OD 600 is 0.5-0.8. Add IPTG to a final concentration of 0.5mM and induce the expression of fusion protein at 25°C overnight to obtain the induced BL21 / pD441-WT bacterial solution. No IPTG was added to the blank control group bacterial solution.
[0099] The BL21 / pD441-WT bacterial solution was centrifuged at 8000rpm / min for 10min, the supernatant was discarded, the precipitated bacteria were collected, and the cells were resuspended in buffer (50mM KPO4, 500mMNaCl, 10mM imidazole, 5% Glycerol, PH 7.0), and PMSF (final concentration 0.5mM) was added. Then, the bacteria were crushed using an ultrasonic crusher, with a working time of 40min, a power of 200W, ultrasonic 1S and stop 2S, and an alarm temperature of 15°C. After the ultrasonic crushing was completed, the cell crushing liquid was placed in a 80°C water bath for 20min, and it was noted that it was regularly mixed during the period to ensure uniform heating; 12000rpm / min, 4°C centrifuged for 30min, the supernatant was filtered with a 0.22um filter membrane, and the filtrate was collected as the crude cell extract.
[0100] The crude cell extract was loaded at an appropriate flow rate for Ni column affinity chromatography (affinity chromatography pre-packed column HisTrap FF, 5 ml, 17-5255-01, GE healthcare). After loading, the sample was equilibrated with buffer 1 for 5CV; eluted with 3% buffer 2 (50mMKPO4, 1M NaCl, 5% Glycerol, PH 7.0) for 5CV; and eluted with 50% buffer 2 for 5CV. The Ni column affinity chromatography eluate corresponding to the peak value greater than or equal to 100mAU was collected.
[0101] The eluate corresponding to the peak value greater than or equal to 100 mAU was loaded at a certain flow rate for ion exchange chromatography (ion exchange prepacked column HiTrap Q HP, 5 ml, 17-1154-01, GE healthcare). After loading, buffer 2 was used for equilibration for 5CV, and linear elution was performed from 0% buffer 2 to 60% buffer 2. The ion exchange chromatography eluate corresponding to the peak value greater than or equal to 100 mAU was collected.
[0102] The ion exchange chromatography eluate corresponding to the peak value greater than or equal to 100mAU was subjected to gel chromatography (gel chromatography prepacked column HiPrepSephacryl S-100HR, 26mm, 17-1194-01, GE healthcare), first washed with 20% ethanol for 3CV, washed with water for 3CV, equilibrated with 100% buffer 3 (20mMTris, 200mMKCl, 0.2mM EDTA, 10% Glycerol, PH7.4) for 3CV and then loaded, and then eluted with buffer 3 for 1.5CV, and the eluate collected was the purified wild-type KOD DNA polymerase fusion protein.
[0103] The purified wild-type KOD DNA polymerase fusion protein was subjected to SDS-PAGE (5% concentrated gel and 12% separated gel), the protein sample was mixed with SDS-PAGE protein loading buffer (5X), treated at 95°C for 5 minutes, and then loaded. Figure 2 As shown, 1 is a protein marker (Page Ruler Prestained Protein Ladder, 26616, Thermo Scientific), 2 is 10 μl 1 mg / ml purified wild-type KOD DNA polymerase fusion protein, and 3 is 10 μl 0.05 mg / ml purified wild-type KOD DNA polymerase fusion protein diluted 20 times. From the protein electrophoresis results, it can be seen that the protein size in lanes 2 and 3 is about 91.5 KDa, which is consistent with the molecular weight reported in the literature.
[0104] The protein gel after electrophoresis was analyzed for protein purity using Quantity one software, and the purity of the wild-type KOD DNA polymerase fusion protein after purification could reach 95% or above.
[0105] The uninduced BL21 / pD441-WT bacterial solution did not produce the target protein of about 91.5 KDa.
[0106] In the control group, the empty vector pD441-pelB was introduced into E. coli BL21 to obtain BL21 / pD441-pelB. The above method was used to express and purify the protein, but the target protein of about 91.5 KDa was not obtained.
[0107] 2. Preparation of KOD DNA polymerase mutant fusion protein
[0108] The KOD DNA polymerase mutant KOD01 (amino acid sequence is sequence 3) is a protein obtained by replacing the amino acid sequence (sequence 1) of the wild-type KOD DNA polymerase by mutating the leucine (L) at position 408 to isoleucine (I), and the tyrosine (Y) at position 409 to alanine (A).
[0109] The KOD DNA polymerase mutant KOD01 encoding gene (nucleotide sequence is sequence 4) is a nucleotide sequence (sequence 2) of the wild-type KOD DNA polymerase encoding gene, wherein the leucine (L) codon at position 408 in the nucleotide sequence (sequence 2) corresponding to the amino acid sequence sequence 1 is mutated to an isoleucine (I) codon, and the tyrosine (Y) codon at position 409 is mutated to an alanine (A) codon.
[0110] The KOD DNA polymerase mutant (amino acid sequence is sequence B or C) is a protein obtained by replacing at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten ... DNA polymerase triple-point combination mutant, and so on.
[0111] The KOD DNA polymerase mutant encoding gene is a nucleic acid obtained by mutating the codons of one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least ten, at least ten, at least ten, at least ten, at least ten, at least ten, at least ten, at least ten, at least ten, at least ten, at least ten, at least ten, at least ten, at least ten, at least ten, at least ten, at least ten, at least ten, at least ten, at least ten, at least ten, at least ten, at least ten, at least ten, at least ten, at least ten, at least ten, at least ten, at least ten, at least ten, at least ten, at least ten, at least ten, at least ten, at least ten, at least ten, at least ten, at least ten, at least ten, at least ten, at least ten, at least ten, at least ten, at least ten, at least ten, at least ten, at least ten, at least ten, at least ten, at least ten, at least ten, at least ten, at least ten, at least ten, at least ten, at least ten, at least ten, at least ten, at least ten, at least ten, at least ten
[0112] The wild-type KOD DNA polymerase can be subjected to site-directed mutagenesis to obtain a KOD DNA polymerase mutant, or it can be obtained by other existing methods.
[0113] 1. Preparation of recombinant vector expressing KOD-type DNA polymerase mutant
[0114] The recombinant vector expressing different KOD-type DNA polymerase mutants is obtained by recombining different KOD-type DNA polymerase mutant protein encoding genes fused with a His tag into the vector pD441-pelB. The obtained vector, which is fused with different point mutant protein encoding genes of the His tag, is expressed through the signal peptide on the vector pD441-pelB.
[0115] The amino acid sequence of each KOD-type DNA polymerase mutant fusion protein is a sequence obtained by connecting six His tags to the C-terminus of the KOD-type DNA polymerase mutant.
[0116] The nucleotide sequence of the different KOD-type DNA polymerase mutant protein encoding genes fused with the His tag is a sequence obtained by connecting the 3' end of the different KOD-type DNA polymerase mutant protein encoding genes to 6 His tag codons.
[0117] The following takes a single point mutant as an example, as shown in Table 1.
[0118] Table 1 shows the mutation positions and mutation information of KOD DNA polymerase single point mutants
[0119]
[0120]
[0121] KOD-type DNA polymerase mutants, taking multi-point mutants as an example, are shown in Table 2 below.
[0122] 2. Construction of recombinant bacteria
[0123] The same as the method 2 in the above one, the recombinant vector expressing different KOD-type DNA polymerase mutants prepared in the above one is introduced into BL21 to obtain recombinant bacteria expressing different KOD-type DNA polymerase mutant fusion proteins.
[0124] 3. Expression and purification of mutants
[0125] The same as the expression and purification method of the wild-type KOD DNA polymerase fusion protein described above, the recombinant bacteria expressing different KOD DNA polymerase mutant fusion proteins prepared in 2 above were expressed and purified to obtain different KOD DNA polymerase mutant fusion proteins.
[0126] The different KOD DNA polymerase mutant fusion proteins were tested by SDS-PAGE (5% concentrated gel and 12% separated gel) to obtain the target protein. The protein gel after electrophoresis was analyzed for protein purity using Quantity one software, and the purity of the different KOD DNA polymerase mutant fusion proteins was found to be 95% or above.
[0127] Example 2: Performance testing of recombinant KOD DNA polymerase mutant fusion protein
[0128] 1. Detection of the polymerization activity of the recombinant KOD DNA polymerase mutant fusion protein on the incorporation of a modified single base.
[0129] The polymerase activity was detected according to the method of Nishioka, M., et al. (2001. J. Biotechnol. 88). One unit of enzyme activity was defined as the amount of acid-insoluble substances generated by polymerizing 10 nmol dNTP in a 50 μl reaction system at 75° for 30 min.
[0130] In this example, dATP (modified) labeled with Cy3 fluorescent dye and DNA chain (DNA-Cy5) labeled with Cy5 fluorescent dye were used to simulate the incorporation of modified nucleotides in the SBS sequencing process, and the relative reaction rates of the recombinant KOD DNA polymerase mutants were detected using an ELISA instrument. The Michaelis-Menten kinetic curves of each mutant were approximately drawn, and Km and Kcat / Km were calculated. The specific experimental method is as follows:
[0131] Reaction Buffer: 20mM Tris-HCl, 10mM (NH4)2SO4, 10mM KCl, 2mM MgSO4 pH 8.5@25℃.
[0132] The reaction system is: 1 μg of KOD polymerase mutant fusion protein and reaction solution with different gradient concentrations of 1-8 μM dATP (modified).
[0133] Reaction temperature: 40℃
[0134] Reaction time: 1h.
[0135] After the reaction is completed, the data table and enzyme activity curve can be directly exported, the reaction rate of its relative fluorescence value can be approximately calculated, and then the kinetic fitting software can be used to fit the kinetic curve.
[0136] The above polymerization reaction was carried out by taking wild-type KOD DNA polymerase fusion protein and KOD DNA polymerase mutant fusion protein as examples. The KOD DNA polymerase mutants are shown in Table 2 below, which contain the KOD DNA polymerase single point mutants and multi-point mutants in Table 1: KOD01, AB60, AB70, AB71, CD72, CD73, EF74, EF75, EF76, GH77, GH78.
[0137] Table 2 KOD DNA polymerase multi-point mutants
[0138]
[0139]
[0140]
[0141] The specific mutation positions and methods of the combined mutants shown in Table 2 are as follows:
[0142] The amino acid sequence of AD90 is that the arginine at position 709 of sequence A is mutated to serine; and the valine at position 589 is mutated to histidine;
[0143] The amino acid sequence of AB60 is as follows: the arginine at position 709 of sequence A is mutated to serine; the valine at position 589 is mutated to histidine; and the alanine at position 485 is mutated to glutamic acid;
[0144] The amino acid sequence of AB70 is as follows: the threonine at position 676 of sequence A is mutated to lysine; the valine at position 589 is mutated to histidine; the valine at position 680 is mutated to methionine; and the alanine at position 485 is mutated to glutamic acid;
[0145] The amino acid sequence of AB71 is as follows: the lysine at position 674 of sequence A is mutated to leucine, the valine at position 589 is mutated to histidine, the valine at position 680 is mutated to methionine, and the alanine at position 485 is mutated to glutamic acid;
[0146] The amino acid sequence of AD80 is that the valine at position 589 of sequence A is mutated to histidine; the valine at position 680 is mutated to methionine; and the arginine at position 709 is mutated to serine;
[0147] The amino acid sequence of CD72 is as follows: the 676th threonine of sequence A is mutated to lysine, the 589th valine is mutated to histidine, the 680th valine is mutated to methionine, the 384th tyrosine is mutated to phenylalanine, and the 485th alanine is mutated to glutamic acid.
[0148] The amino acid sequence of CD73 is that the valine at position 389 of sequence A is mutated to isoleucine, the lysine at position 674 is mutated to leucine, the valine at position 589 is mutated to histidine, the valine at position 680 is mutated to methionine, and the alanine at position 485 is mutated to glutamic acid.
[0149] The amino acid sequence of AD80 is as follows: the valine at position 589 of sequence A is mutated to histidine; the valine at position 680 is mutated to methionine; the threonine at position 676 is mutated to lysine; the serine at position 383 is mutated to threonine; and the tyrosine at position 384 is mutated to phenylalanine;
[0150] The amino acid sequence of EF74 is as follows: the lysine at position 674 of sequence A is mutated to leucine, the valine at position 589 is mutated to histidine, the valine at position 680 is mutated to methionine, the serine at position 383 is mutated to threonine, the tyrosine at position 384 is mutated to phenylalanine, and the alanine at position 485 is mutated to glutamic acid.
[0151] The amino acid sequence of EF75 is as follows: the 349th threonine of sequence A is mutated to phenylalanine, the 589th valine is mutated to histidine, the 676th threonine is mutated to lysine, the 680th valine is mutated to methionine, the 496th tyrosine is mutated to leucine, and the 485th alanine is mutated to glutamic acid.
[0152] The amino acid sequence of EF76 is as follows: the 589th valine of sequence A is mutated to histidine, the 676th threonine is mutated to lysine, the 680th valine is mutated to methionine, the 383rd serine is mutated to threonine, the 384th tyrosine is mutated to phenylalanine, and the 485th alanine is mutated to glutamic acid.
[0153] The amino acid sequence of GH77 is as follows: the 589th valine of sequence A is mutated to histidine, the 676th threonine is mutated to lysine, the 680th valine is mutated to methionine, the 383rd serine is mutated to threonine, the 384th tyrosine is mutated to phenylalanine, the 709th arginine is mutated to serine, and the 485th alanine is mutated to glutamic acid.
[0154] The amino acid sequence of GH78 is as follows: the valine at position 389 of sequence A is mutated to isoleucine, the valine at position 589 is mutated to histidine, the threonine at position 676 is mutated to lysine, the valine at position 680 is mutated to methionine, the serine at position 383 is mutated to threonine, the tyrosine at position 384 is mutated to phenylalanine, and the alanine at position 485 is mutated to glutamic acid.
[0155] The KOD-type DNA polymerase mutant fusion protein is obtained by adding six his tags to the C-terminus of the respective KOD-type DNA polymerase mutant.
[0156] The results of the polymerase activity of the KOD-type DNA polymerase mutant fusion protein are shown in Table 2. It can be seen that the KOD-type DNA polymerase mutant has polymerase activity.
[0157] The polymerization activities of other mutants were also improved compared with the wild type.
[0158] 2. Kinetics of single modified base incorporation into KOD-type DNA polymerase mutant fusion proteins
[0159] In this example, dATP (modified) labeled with Cy3 fluorescent dye and DNA chain (DNA-Cy5) labeled with Cy5 fluorescent dye were used to detect the relative reaction rate of recombinant KOD DNA polymerase mutants using a microplate reader, and the Michaelis-Menten kinetic curve of each mutant was approximately drawn to calculate Km and Kcat / Km. The specific experimental method is as follows:
[0160] Reaction Buffer: 20mM Tris-HCl, 10mM (NH4)2SO4, 10mM KCl, 2mM MgSO4 pH 8.5@25℃.
[0161] The reaction system is: 1 μg of KOD polymerase mutant fusion protein and reaction solution with different gradient concentrations of 1-8 μM dATP (modified).
[0162] Reaction temperature: 40℃
[0163] Reaction time: 1h.
[0164] After the reaction is completed, the data table and enzyme activity curve can be directly exported, the reaction rate of its relative fluorescence value can be approximately calculated, and then the kinetic fitting software can be used to fit the kinetic curve.
[0165] The wild-type KOD DNA polymerase fusion protein (KOD-WT) was used as a control.
[0166] The kinetic parameters of KOD DNA polymerase mutant fusion protein are shown in Table 3 below, and it can be seen that KOD DNA polymerase mutant mutant has higher polymerization activity relative to wild type. Specific experimental results can refer to Table 3 below, and the kinetic test results of KOD DNA polymerase mutant show greater potential than wild type. In the sequencing process, the faster the catalytic efficiency of the enzyme reaction, the greater the value of Kcat / km, which can accelerate the reaction to a certain extent and shorten the sequencing reaction time. From the experimental results, it can be seen that in terms of enzyme catalytic efficiency, KOD DNA polymerase mutant has a better improvement than wild-type KOD DNA polymerase.
[0167] Table 3 Kinetic test results of KOD DNA polymerase mutants
[0168]
[0169]
[0170]
[0171] The Kcat / Km of other mutants were also improved compared with the wild type.
[0172] The larger the ratio of Kcat / km, the faster the enzyme converts the substrate, so the better its performance in SBS sequencing.
[0173] Industrial Applications
[0174] The experiment of the present invention proves that the present invention aims at further extending the sequencing read length, shortening the reaction time and other improvement goals, and further transforms the KOD DNA polymerase on the basis of previous work, protects the original functional sites involved in this region of the DNA polymerase B family, ensures that it can still complete the original basic functions, improves the reaction rate of the DNA polymerase in sequencing, and increases the reaction read length. Compared with the wild-type DNA polymerase, the recombinant DNA polymerase shows advantages such as a stronger reaction rate and better catalytic efficiency in catalysis.
Claims
1. A protein, which is the protein shown in A below or its derivative: A) The protein shown is a protein having DNA polymerase activity obtained by mutating the leucine at position 408 to isoleucine and the tyrosine at position 409 to alanine in the amino acid sequence of wild-type KOD DNA polymerase; The derivative of the protein shown in A) is a protein derived from A) with a tag sequence added to the end of the amino acid sequence of the protein shown in A) and having DNA polymerase activity; The amino acid sequence of the wild-type KOD DNA polymerase is sequence 1.
2. A protein, which is any one of the following proteins B1)-B3): The protein shown in B1) is a protein having DNA polymerase activity obtained by replacing the leucine at position 408 with isoleucine, the tyrosine at position 409 with alanine, and the asparagine at position 735 with histidine in the amino acid sequence of the wild-type KOD DNA polymerase; B2) The protein shown is a protein having DNA polymerase activity obtained by mutating the leucine at position 408 to isoleucine, the tyrosine at position 409 to alanine, and replacing the serine at position 383 to threonine in the amino acid sequence of the wild-type KOD DNA polymerase; The protein shown in B3) is a protein derived from B1) or B2) with a tag sequence added to the end of the amino acid sequence of the protein shown in B1) or B2) and having DNA polymerase activity; The amino acid sequence of the wild-type KOD DNA polymerase is sequence 1.
3. A DNA molecule encoding the protein according to claim 1 or 2.
4. An expression cassette, recombinant vector or recombinant bacterium containing the DNA molecule according to claim 3.
5. Use of the protein according to claim 1 or 2 in at least one of the following 1) to 5): 1) Acts as a DNA polymerase; 2) Catalyze DNA replication; 3) Perform nucleic acid sequencing; 4) Preparation of products for catalyzing DNA replication; 5) Prepare products for nucleic acid sequencing.
6. The DNA molecule of claim 3 or the expression cassette, recombinant vector or recombinant bacterium of claim 4 is at least one of the following 1) to 5). one Application in species: 1) Prepare DNA polymerase; 2) Catalyze DNA replication; 3) Perform nucleic acid sequencing; 4) Preparation of products for catalyzing DNA replication; 5) Prepare products for nucleic acid sequencing.
7. The use according to claim 5 or 6, characterized in that: The sequencing is SBS sequencing; The nucleic acid is DNA or RNA.
Citation Information
Patent Citations
Modified polymerases for improved incorporation of nucleotide analogues
CN106536728A
Modified polymerases for improved incorporation of nucleotide analogues
CN107002051A
Recombinant DNA polymerase for improved incorporation of nucleotide analogues
CN108018270A
Recombinant DNA polymerase for improved incorporation of nucleotide analogues
US20180119115A1
Modified polymerase
WO2016153053A1
